Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
| Sponsor Type | Funding Program Title | Amount and Duration | Description | Deadline | |
|---|---|---|---|---|---|
| Tri-Agency | SickKids Foundation-CIHR Operating Grant: New Investigator Grants in Child and Youth Health (2024) | Up to $100,000 per year for up to 3 years. | This supports new investigators for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children's health outcomes. | April 22, 2024. | |
| Tri-Agency | CIHR Operating Grant: Knowledge Mobilization in Diabetes Prevention and Treatment | Up to $125,000 for up to one year. | The goal of this funding opportunity is to enhance knowledge mobilization in the field of diabetes, focusing on evidence integration into health services, programs, and policies. This funding opporunity will also provide researchers and knowledge users an opportunity to work collaboratively to improve prevention and care of pople at rick of, or living with, diabetes in Canada. | May 1, 2024. | |
| Tri-Agency | CIHR Catalyst Grant: Development and Validation of New Biomedical Techniques and Technologies | Up to $150,000/year for up to 2 years. | New biomedical technology development and validation was identified as a major gap in funding that is required to advance biomedical research in Canada; this gap will be addressed through the catalyst grants funded through this funding opportunity. | Registration: May 8, 2024. Full application: July 9, 2024. | |
| Tri-Agency | CIHR Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C | Up to $100,000 per year for one year. | The overall goal of this grant is to strengthen the current landscape of STBBI research in Canada, and to build capacity and spur innovation in this field, with a specific focus on STBBI of public health relevance beyond the fields of HIV and hepatitis C and in alignment with the CIHR HIV/AIDS and STBBI Strategic Plan 2022-2027. | May 9, 2024. | |
| Tri-Agency | CIHR Team Grant: HIV/AIDS and STBBI Community-Based Research Team Grants | LOI Stage: Up to $100,000 for 1 year. Full Application Stage: Up to $200,000 per year for up to 5 years | The purpose of the funding opportunity is to support a diversity of CBR teams to build and strengthen capacity for CBR and knowledge mobilization activities that are centred in the self-determined priorities of the communities and will lead to improved health outcomes for key populations disproportionately affected by STBBI in Canada. | Letter of intent: June 13, 2024. Full application: September 4, 2025. | |
| Tri-Agency | CIHR Operating Grant: Early Career Researchers (ECRs) in Human Development, Child and Youth Health | $50,000/year for up to 3 years. | The goal of this funding opportunity is to build research capacity, generate new knowledge, and support knowledge mobilization in human development, child and youth health by funding operating grants to ECRs. The program will fund research across the four CIHR pillars that has the potential to have a significant impact on human development, child and youth health. | Registration: September 4, 2024. Full application: September 24, 2024. | |
| Tri-Agency | NSERC: Idea to Innovation (I2I) Grant | Market assessment ($15,000), Phase I ($125,000), Phase Ib ($60,000), Phase IIa ($125,000), Phase IIb ($350,000). | This opportunity aims to accelerate the pre-competitive development of promising technology originating from the university and college sector, and promote its transfer to a new or established Canadian company. | September 16, 2024. | |
| Tri-Agency | CIHR Team Grant: Biomedical Research for HIV/AIDS and STBBI | $400,000/year for up to 5 years (Team Grants); $750,000/year for up to 5 years (Large Team Grants). | This funding opportunity will support applications relevant to innovative technologies and next-generation interventions for STBBI across the cascade of care, from prevention to detection, to treatment and cure. This includes, but is not limited to, discovery research in biology, immunology, and pathology that contributes to the design, development, and implementation of interventions in the following two research areas: Next-Generation Therapeutic Interventions and Next-Generation Prevention Technologies. | September 17, 2024. | |
| Tri-Agency | NSERC Alliance Grants | $20,000 to $1 million per year for 1-5 years | Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Tri-Agency | NSERC Alliance International | Catalyst Grants: $25,000 for 1 year. Collaboration Grants: Up to $100,000 per year for up to 3 years. | These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector ad t oestablish and grow international research collaborations and projects that have a high potential for impact in NSE disiplines. | No Deadline | |
| Tri-Agency | CIHR Notice of Upcoming Funding Opportunity: Community Based Research in Climate Change Priority Areas | Up to $125,000 for one year. | The purpose of this funding opportunity is to support the partnered work of communities and researchers in knowledge development and capacity-building initiatives of relevance to communities working to combat the differential health impacts of climate change. This will support activities relevant to one of the following research areas: Climate Justice; Alternative Diagnoses of Lyme Disease; Food Security in Northern Communities; and Health Impacts of Climate Change on Older Adults. | Anticipated Deadlines:* Registration: Late summer 2024. Application: Fall 2024. | |
| Other Canadian | J. P. Bickell Foundation Medical Research Grant | Range from $25,000 - $80,000. | For medical research, with a focus on innovative basic/translational research projects led by early career researchers. Please note that Unity Health can submit only one application for this grant. To be considered, send a summary of your proposed project/program (maximum 1 page) to VPRI@unityhealth.to by March 22, 2024. | Sponsor Deadline: April 30, 2024. | |
| Other Canadian | Weston Brain Institute: Rapid Response 2024 program | Up to $300,000 over 18-24 months. | This opportunity aims to catalyze and scale science-based approaches to significantly improve the health and well-being of Canadians. The Rapid Response program is designed to provide seed funding to catalyze novel, high-risk, high-reward translational research that accelerates the development of therapeutics or tools for neurodegenerative diseases of aging (NDAs). The program information session will be held on April 2, 2024 at 1pm ET. | Letter of intent: April 30, 2024. Full application: August 7, 2024. | |
| Other Canadian | Improving the care and outcomes of residents of Canada living with metastatic NSCLC | -- | Pfizer, the Lung Health Foundation (LHF), Lung Cancer Canada (LCC), and the Quebec Lung Association (QLA) are jointly issuing a Quality Improvement Request for Proposal (RFP). Grant funding and general oversight of the funded projects will be provided directly from Pfizer on behalf of Pfizer and the collaborators. The goal of this RFP is to improve health equity for residents of Canada living with metastatic NSCLC by addressing challenges. | April 30, 2024. | |
| Other Canadian | Canadian Foundation for Pharmacy (CFP) Innovation Fund Grant | Not specified. Up to $100,000 will be available. | This supports a pharmacist engaged in research or grassroots innovation that seeks to advance the pharmacy profession in ways that can demonstrably improve the health of Canadians. | Letter of Intent: May 8, 2024. Application (by invitation): TBA. Expected by the end of July. | |
| Other Canadian | Ontario Institute for Cancer Research (OICR): Cancer Therapeutics Innovation Pipeline (CTIP) – Early Validation Projects | Up to $150,000 per year for a maximum of 2 years. | Deliver robust translational evidence that a Target-of-Interest (TOI) is associated with a specific cancer type(s) based on data from knowledge bases and from studies demonstrating that perturbation of the TOI in relevant cell-based models produces anti-cancer effects sufficient to trigger a drug discovery campaign. | Letter of Intent: May 16, 2024 by 5 p.m. ET Full application: August 29, 2024 by 5 p.m. ET | |
| Other Canadian | Ontario Institute for Cancer Research (OICR): Cancer Therapeutics Innovation Pipeline (CTIP)- Early Accelerator projects | Up to $150,000 for a maximum of one year. | Deliver a validated primary assay to enable initial screening of molecules against a defined target. Preliminary evidence of linearity of results between the primary assay and supporting secondary assays under development is also required. | Letter of Intent: May 16, 2024 by 5 p.m. ET Full application: August 29, 2024 by 5 p.m. ET | |
| Other Canadian | University of Toronto Early Stage Technology Program (UTEST) Program: 2024 Applications | Investment funding of up to $150,000, incubation space, intense entrepreneurial education provided by MaRS, corporate and intellectual property legal support, mentoring and business strategy support. | Applications are open to companies with one or more founders affiliated with the University of Toronto, who are: Current University of Toronto students; Current University of Toronto faculty members and Recent University of Toronto graduates (within two years) | May 30, 2024. | |
| Other Canadian | Terry Fox New Investigator Awards | Up to $150,000/year for 3 years. | This opportunity will support outstanding new researchers as they develop their careers as independent research scientists or clinician scientists. This is intended for investigators who are within the first five years of their first faculty-level appointment in Canada and enable recipients to undertake high-quality cancer research with mentorship from two senior investigators. | Registration of intent: June 3, 2024. Full application: August 5, 2024. | |
| Other Canadian | U of T Manchester-Melbourne-Toronto (MMT) Research Fund 2024 | CAD $14,000 to support Toronto applicants. Duration of 18 months. | The University of Manchester, the University of Melbourne, and U of T are contributing matching funds to support collaborative bilateral and trilateral research initiatives through a joint call for proposals. Applicants from all disciplines are welcome to apply. | June 3, 2023. | |
| Other Canadian | Diabetes Canada: 2024 End Diabetes Awards | Up to $150,000 per year for 3 years. | Diabetes Canada is proud to be a leading supporter of diabetes research in Canada. End Diabetes Awards fund research to enhance our understanding of diabetes and its prevention, treatment, management, and cure. Diabetes Canada accepts funding proposals from all four pillars of health research. | June 7, 2024. | |
| Other Canadian | Dorothy Killam Research Fellowships | $80,000/year for a total of up to $160,000 for 2 years. | To support scholars of exceptional ability by granting them time to pursue research projects of broad significance and widespread interest within the disciplines of the humanities, social sciences, natural sciences, health sciences, engineering or studies linking any of these disciplines. | June 13, 2024. | |
| Other Canadian | Killam NRC Paul Corkum Fellowship | $100,000 + an additional grant of up to $50,000 for travel and knowledge dissemination costs; the NRC co-Pl could also receive up to $50,000. | This fellowship will create opportunities for mid-to-late career Canadian and international scholars to collaborate with NRC researchers. The Fellowship provides teaching and administrative release time for 12 months for scholars who have demonstrated outstanding research ability, and who are proposing projects that are aligned with one or more NRC Challenge Programs. | June 20, 2024. | |
| Other Canadian | Canadian Cancer Society Breakthrough Team Grants - Transforming the Future of Metastatic Cancer | Up to $1.5M/year for 5 years. | The intent of this grant model is to bring passionate and talented teams of scientists, clinicians, patient partners, and knowledge users from across disciplines to work together to address important gaps in cancer research that will be transformational for people affected by the disease. The program has two themes, which are intended to be represented by at least two funded Breakthrough Teams: To develop a better understanding of the biology of and mechanisms associated with cancer cell dormancy and to better support people living with advanced or metastatic disease through the course of their disease. | Letter of intent: June 27, 2024. Full application: October 15, 2024. | |
| Other Canadian | Terry Fox New Frontiers Program Project Grants | Up to $2.4M for 3-5 years (New Applications); Up to $7.5M for 5-7 years (Renewing Applications). | These programs support Canadian research teams exploring new frontiers in cancer research (i.e., breakthrough and transformative biomedical, clinical and translational research which may form the basis for innovative cancer prevention, diagnosis and/or treatment). This Request for Applications support program projects comprised of a minimum of three independent researchers and their individual research projects that may also include one or more technology (or ‘core’) platforms that will be used by the projects in pursuit of an important cancer research topic. | Letter of intent: July 8, 2024. Full application: November 18, 2024. | |
| Other Canadian | Sigma/Canadian Nurses Foundation Grant | Up to USD $5,000. | This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. | December 1, 2024. | |
| Other Canadian | Multiple Sclerosis Society of Canada: Contract Research Organization (CRO) Grant | Up to $100,000 to pay for CRO services for up to a 1 year term. | This will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS. | Open competition with no set deadline. | |
| Other Canadian | Grand Challenges Canada: Transition To Scale (TTS) Request for Proposals | Range from $250,000 to $3M for 6 months up to 2 years | This seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. | Concept notes accepted on a rolling basis | |
| Other Canadian | University of Toronto Institutional Strategic Initiatives (ISI) | From $50,000-$300,000 per year for up to 3 years. | ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. | Ongoing | |
| Other Canadian | Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs | -- | The NRC offers potential opportunities for collaboration in the following areas: Aging in Place, Artificial Intelligence for Design, Disruptive Technology Solutions for Cell and Gene Therapy, High-throughput and Secure Networks, and Pandemic Response. | Ongoing | |
| Other Canadian | Rare Diseases: Models & Mechanisms Network Catalyst Grants | $25,000 | Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher. | Continuous | |
| Other Canadian | Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant | Health Research Grant: Up to $250,000 for 3 years. New Investigator Grant: Up to $300,000 for 3 years. | Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. | Rolling deadline | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Leveraging Grant | Up t0 $80,000 | To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Team Development Grants | Up to $10,000 for up to 18 months | To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs. | Rolling call | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Small Grants | Up to $10,000 for up to 1 year | To support small developmental initiatives typically intended to lead to major grant applications. | October 1st and May 1st each year | |
| Other Canadian | Telus Funds | Various | For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition. | Various | |
| Other Canadian | Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program | Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.) | This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. If you are interested, please contact Samar Saneinejad at Samar.Saneinejad@unityhealth.to | No Deadline | |
| International | CHEST Foundation: Various Opportunities | $10,000 - $150,000 (check opportunities for amounts) | This foundation offers several opportunities within the area of treatment and/or management of chest diseases and patient care. For all grant applications, CHEST membership is required at the time of application. | April 22, 2024. | |
| International | Cystic Fibrosis Foundation (CFF): Health Equity Team Science Award | Up to USD $200,000 per year for up to 4 years, plus an additional 12% indirect costs per year. The lead institution may request up to USD $50,000 in additional direct costs per year to support an administrative core. | The research projects should have the potential to improve our understanding of or have a positive impact on identified barriers to optimal health outcomes for all people with CF related to race and ethnicity, sexual orientation or gender, or socioeconomic status. NOTE: Applicants must speak with program staff prior to submission to ensure the project design is in line with the goals of this request for application | Letter of Intent: April 23, 2024. Full Application: September 17, 2024. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Early Career Grant For Psychologists Investigating Serious Emotional Disturbance (SED) | USD $22,000. | Supports early career psychologists conducting research in the area of early intervention and treatment for serious emotional disturbance in children. Applicants must be early career psychologists (no more than 10 years postdoctoral. | April 24, 2024. | |
| International | Mark Foundation for Cancer Research: Emerging Leader Award | USD $250,000/year for 3 years. | This opportunity supports innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. | Letter of intent: April 29, 2024. Full application: July 22, 2024. | |
| International | Oncomine Clinical Research Grant Program | Up to USD $200,000. | This program supports investigator-initiated studies and education projects in oncology research, with the goal to increase high-quality molecular profiling and to help democratize access to sequencing technologies. The current competition is accepting proposals addressing unmet diagnostic needs using next-generation sequencing for both solid and hematological cancers. | April 30, 2024. | |
| International | World Federation of Hemophilia: World Bleeding Disorders Registry (WBDR) Research Support Program (RSP) | Between USD $2,000-$5,000 per project for 1 or 2 years. | This is designed to motivate and support hemophilia treatment centres (HTC) to collect, analyze and use their WBDR data. The program is open to recognized HTCs from any country, as long as they are registered in the WBDR. Only one application per HTC is accepted, per cycle. | May 1, 2024. | |
| International | American Society of Hematology (ASH) Junior Faculty Scholar Award | Up to USD $150,000 for 2 or 3 years. | This is for applicants who hold independent faculty level positions. It provides partial salary or other research support during that critical period required for completion of training and achievement of status as an independent investigator. | Letter of intent: May 1, 2024. Full application: August 1, 2024. | |
| International | American Psychological Association (APA): Norine Johnson, Ph.D., Psychotherapy Research Grant | $15,000 | This program awards grants to early career psychologists (ECPs; within 10 years post earning the doctoral degree) for research on psychotherapy. All aspects of psychotherapy research can be supported, including the psychotherapy relationship, psychotherapy process, or psychotherapy outcomes. | May 1, 2024. | |
| International | The International Centre for Responsible Gaming (ICRG): Seed Grant for Research on Gambling Disorder and Responsible Gambling | Up to $40,000 for 1 year | This is to support a variety of research activities, exploring the etiology, prevention and treatment of gambling disorder, and the development and evaluation of responsible gambling strategies, such as: Pilot and feasibility studies, Secondary analysis of existing data, Small, self-contained research projects, Development of research methodology, Development of new research technology. | May 1, 2024. | |
| International | Foundation for Physical Medicine & Rehabilitation (Foundation for PM&R): Various Opportunities | USD $10,000-$30,000 (check opportunities for amounts) | This foundation offers several opportunities within the area of physiatric research to increase our understanding of the underlying mechanisms of disability, and determine the best interventions to maximize health and improve function for people with disabilities | May 1, 2024. | |
| International | Cystic Fibrosis Foundation (CFF): Path to a Curet (PTAC) - PTAC Research Grant | Up to USD $150,000/year for up to 3 years. | This is intended to facilitate or enable the development of new information that may contribute to the development of new therapies for CF, especially projects focused on advancing CFTR repair and replacement strategies. | May 2, 2024. | |
| International | Cystic Fibrosis Foundation (CFF): Path to a Cure (PTAC) - PTAC Pilot and Feasibility Award | Up to USD $50,000/year for up to 2 years. | This is to support projects that will develop and test new hypotheses and/or new methods that could eventually contribute to the development of a cure for CF, and to support promising new investigators as they establish themselves in research | May 2, 2024. | |
| International | Cystic Fibrosis Foundation (CCF): Pilot and Feasibility Award | Up to USD $50,000/year up to 2 years. | This supports projects that will develop and test new hypotheses and/or new methods that could eventually contribute to the development of a cure for CF and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. | May 2, 2024 (Spring cycle); December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CCF): Research Grant | Up to USD $150,000/year for up to 3 years. | This is intended to facilitate or enable the development of new information that may contribute to the development of new therapies for CF, especially projects focused on advancing CFTR repair and replacement strategies. Proposals must be hypothesis driven and contain sufficient preliminary data to justify support from the Cystic Fibrosis Foundation. | May 2, 2024 (Spring cycle); December 5, 2024 (Fall cycle). | |
| International | Cystic Fibrosis Foundation (CCF): Postdoctoral Research Fellowships | Up to USD $75,000/year for up to 2 years. | This is intended to enable research training in new research areas and methods to advance the scientific knowledge of the applicant and to collect data to enable their transition into an independent research career. | May 2, 2024 (Spring cycle); December 5, 2024 (Fall cycle). | |
| International | American Academy of Pediatrics (AAP): Neonatal Resuscitation Program (NRP) Grant Applications: Multiple Opportunities) | $15,000-$50,000 (check opportunites for amounts) | The NRP committee is interested in the effect of this program on neonatal morbidity and motalilty, as well as other interventions that may improve the outcome of neonatal resuscitatin | Intent of Application: May 3, 2024. Full Application: August 2, 2024. | |
| International | 1907 Research Foundation: 1907 Trailblazer Award | $100,000 unrestricted research grant and a $20,000 living stipend | The 1907 Trailblazer Award is an accelerator program for early career scientists in brain health research for psychiatric and neurodegenerative illnesses. | Opens April 15, 2024 Deadline: May 3, 2024 | |
| International | The Obesity Society (TOS) Early Career Research Grant | Up to USD $25,000. | This funds proposals that demonstrate a high likelihood of resulting in new and innovative approaches in obesity research. All applicants must be TOS members in good standing. | Phase 1 (Letter of Intent): May 6, 2024. Phase 2 (Full Proposal; by invitation): TBA. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Discovery Award | Up to USD $275,000 for up to 2 years. | Supports innovative, untested, non-incremental, high-risk / potentially high-reward research that will provide new insights, paradigms, technologies or applications. | Pre-Application: May 6, 2024; Application: May 23, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Investigator Initiated Research Award | Up to USD $1.0 for up to 4 years. | Supports research that will make an important contribution toward research, patient care and/or quality of life for a disease of condition in the Topic Area(s) of interest. | Pre-Application: May 6, 2024; Application: May 23, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Clinical Trial Award | 1) Clinical trial only: funding limit not defined; up to 4 years; 2) Planning Phase with clinical trial: Up to USD $500,000 for the planning phase and up to 12 months for the planning phase; up to 4 years for the clinical trial. | Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. | Pre-Application: May 13, 2024; Application: August 19, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Lifestyle and Behavioral Health Interventions Research Award | Up to USD $3.0M for up to 4 years. | Supports using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance and public health that will enhance patient experience and improve outcomes. | Pre-Application: May 13, 2024; Application: June 6, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Technology/Therapeutic Development Award | Up to USD $4.0M for up to 4 years. | Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life. | Pre-Application: May 13, 2024; Application: June 6, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Peer Reviewed Medical Research Program (PRMRP): Impact Award | Up to USD $2.0M for up to 4 years; Partnering Option up to $2.6M for up to 4 years. | Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from real-world environment to foster clinical applicability in the Topic Area(s) of interest. Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest. | Pre-Application: May 13, 2024; Application: June 6, 2024. | |
| International | Alzheimer's Drug Discovery Foundation: Accelerating Drug Discovery for Frontotemporal Degeneration | USD $300,000-$350,000 for one year. | There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. | Letter of intent: May 13, 2024. Full application: July 22, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Breakthrough Award Levels 4 (BTA4) | Up to USD $15.0M for up to 4 years | -- | Pre-Application: May 14, 2024; Application: August 6, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Breakthrough Award Levels 3 (BTA3) | Up to USD $4.0M or up to USD $5.0M with the Partnering PI Option for up to 4 years; Funding Level 4 and Funding Level 4 with the Partnering PI Option: Up to USD $15 million for up to 4 years. | -- | Pre-Application: May 14, 2024; Application: August 6, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Transformative Breast Cancer Consortium Award (TBCCA) | Up to USD $25.0M for up to 4 years. | -- | Pre-Application: May 14, 2024; Application: August 6, 2024, 2023. | |
| International | American Orthopaedic Society for Sports Medicine (AOSSM): Playmaker Grant | USD $25,000. | This research grant opportunity aims to advance exploratory projects by providing start-up funding, seed money, bridge/gap funding, or supplemental funding for an ambitious investigative team. Criteria and metrics utilized in the proposed study must be determined by best scientific evidence and designed to improve the understanding of an emerging or novel technology in orthopaedic sports medicine. Studies involving human subjects will receive priority. | Letter of Intent: May 15, 2024; Presentation (by invitation): July, 2024 (at annual meeting). | |
| International | American Orthopaedic Society for Sports Medicine (AOSSM): Steven P. Arnoczky Young Investigator Grant | Up to USD $40,000 per year for 2 years. | This aims to train early-career surgeons as principal investigators, perform the primary role in generating the hypothesis, design the experiment, carry it out, and interpret the results with the assistance of an experienced supervisor and/or investigative team. | Pre-Proposal: May 15, 2024; Full Proposal (by invitation): September 1, 2024. | |
| International | Ninth Global Alliance for Chronic Diseases (GACD) Call: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (NCD) | -- | This call focuses on implementation research proposals, to address management of multiple long-term conditions, in the context of non-communicable diseases (NCDs). | First stage proposals: May 15, 2024. Second stage proposals (by invitation): October 3, 2024 | |
| International | Rainwater Charitable Foundation: Rainwater Prize Program - Outstanding Innovation in Neurodegenerative Research | $400,000 | This program aims to increase awareness of critical gaps in neurodegenerative research, attracting and retaining researchers to work on tauopathies and rewarding step-wise scientific achievements that can lead to effective treatments for patients. This prize recognizes investigator(s) whose work is considered a significant contribution to our understanding of tau-related diseases, with an emphasis on research applicable to the primary tauopathies. | May 15, 2024. | |
| International | Rainwater Charitable Foundation: Rainwater Prize Program - Milestone Prize for Advances in Tauopathy Research | Up to $2M. This prize will be awarded upon milestone completion and may or may not be awarded each year. This award may be awarded to individuals or teams of scientists. | This program aims to increase awareness of critical gaps in neurodegenerative research, attracting and retaining researchers to work on tauopathies and rewarding step-wise scientific achievements that can lead to effective treatments for patients. This prize recognizes investigator(s) whose work is considered a significant contribution to our understanding of Tau-related diseases by addressing critical gaps in technology and disease knowledge that will help the scientific community develop effective treatments. | May 15, 2024. | |
| International | Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia & AACR | $206,000 over 2 years | This groundbreaking initiative will fund innovative research aimed at progressing outcomes for women's cancers and invest in the next generation of women scientists who represent the diverse population they serve. By focusing on prevention, detection, diagnostic, and treatment innovations for women’s cancers and advancing outcomes for cancer health disparities. | May 15, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Breakthrough Award Levels 1 and 2 (BTA12) | Funding Level 1: Up to USD $450,000 or up to USD $750,000 with the Partnering PI Option for up to 3 years; Funding Level 2: Up to USD $1.0M or up to USD $1.5M for up to 3 years; Funding Level 2 – Population Science and Prevention Studies with Partnering PI Option: Up to USD $2.0M for up to 4 years. | -- | Pre-Application: May 16, 2024; Application: May 30, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Transformative Breast Cancer Consortium Development Award (TBCCDA) | Up to USD $100,000 for up to 1 year. | -- | Pre-Application: May 16, 2024; Application: May 30, 2024. | |
| International | Oncology Nursing Society (ONS) Foundation: Various Opportunities | USD %50,000-$100,000 (check opporunities for amounts) | This foundation supports research grantsand fellowships to identify and test new insights into patient care. | Letters of intent: May 16, 2024 Full proposal: June 28, 2024 | |
| International | DoD Congressionally Directed Medical Research Programs (CDMRP): FY24 Spinal Cord Injury Research Program (SCIRP) - Clinical Trial Award | Single PI Option: Up to USD $3.0M for up to 4 years; Early-Career Partnering PI Option: Up to USD $3.1M for up to 4 years. | Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI). | Pre-Application: May 20, 2024; Application: August 30, 2024. | |
| International | DoD Congressionally Directed Medical Research Programs (CDMRP): FY24 Spinal Cord Injury Research Program (SCIRP) - Clinical Translational Research Award | Single PI Option: Up to USD $1.25M for up to 3 years; Early-Career Partnering PI Option: Up to USD $1.35M for up to 3 years. | Supports high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary. | Pre-Application: May 20, 2024; Application: August 30, 2024. | |
| International | DoD Congressionally Directed Medical Research Programs (CDMRP): FY24 Spinal Cord Injury Research Program (SCIRP) - Translational Research Award | Single PI Option: Up to USD $1.25M for up to 3 years; Early-Career Partnering PI Option: Up to USD $1.35M for up to 3 years. | Funds studies that accelerate the movement of promising ideas in SCI research toward clinical application. | Pre-Application: May 20, 2024; Application: August 30, 2024. | |
| International | DoD Congressionally Directed Medical Research Programs (CDMRP): FY24 Spinal Cord Injury Research Program (SCIRP) - Investigator-Iniated Research Award | Single PI Option: Up to USD $500,000 for up to 3 years; Early-Career Partnering PI Option: Up to USD $600,000 for up to 3 years. | Funds research that has the potential to make an important contribution to SCI research, patient care, and/or quality of life. | Pre-Application: May 20, 2024; Application: August 30, 2024. | |
| International | DoD: Peer Reviewed Alzheimer's Research Program for FY24 - Transforming Care Award | Up to $1,400,000 for up to 4 years | Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both and clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not refer to medical care (such as medical interventions administered by a physician). | Pre-Application: May 22, 2024; Application: June 20, 2024. | |
| International | DoD: Peer Reviewed Alzheimer's Research Program for FY24 - Transforming Diagnosis Award | Up to $2,000,000 for up to 4 years. | Supports research to reduce barriers and improve diagnosis and prognosis of dementia of AD/ADRD following military service and/or TBI. | Pre-Application: May 22, 2024; Application: June 20, 2024. | |
| International | DoD: Peer Reviewed Alzheimer's Research Program for FY24 - Transforming Research Award | Up to $1,000,000 for up to 3 years. | Supports high-impact research with high impact aimed to identify, validate, and/or mitigate risk factors which may contribute to dementia onset. | Pre-Application: May 22, 2024; Application: June 20, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Era of Hope Scholar Award (EOHS) | Up to USD $3.5M for up to 4 years. | -- | Pre-Application: May 23, 2024; Application: June 4, 2024; Recommendation Letters: June 7, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY24 Breast Cancer Research Program (BCRP): Clinical Research Extension Award (CREA) | Up to USD $5.0M or up to USD $6.0M with the Partnering PI Option for up to 4 years. | -- | Pre-Application: May 23, 2024; Application: June 4, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY24 Amyotrophic Lateral Sclerosis Research Program (ALSRP): Various Opportunities | USD $600,000 - $2,000,000 (check opportunities for amounts) | The ALSRP is guided by a vision to improve treatments and find cures for people with ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports impactful research to develop ALS treatments. | Pre-Application: May 24, 2024; Application: July 10, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionlly Directed Medical Research Programs: The Lung Cancer Research Program (LCRP) - Concept Award | Up to $120,000 for 1 year | Supports highly innovative, non-incremental, high risk/potentially high-reward lung cancer research. | Pre-Application: May 28, 2024; Application: June 17, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionlly Directed Medical Research Programs: The Lung Cancer Research Program (LCRP) - Career Development Award | Up to $375,000 for up to 3 years | Supports early-career, independent investigators to conduct research under mentorship of an experienced lung cancer researcher. | Pre-Application: May 28, 2024; Application: June 17, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionlly Directed Medical Research Programs: The Lung Cancer Research Program (LCRP) - Idea development Award | Up to $525,000 for up to 3 years | Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research. | Pre-Application: May 28, 2024; Application: August 7, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionlly Directed Medical Research Programs: The Lung Cancer Research Program (LCRP) - Translational Research Award | Funding Level 1: Up to USD $900,000 for up to 3 years; Funding Level 2 – Clinical Trial Option: Up to USD $1,200,000 for up to 4 years. | Supports high-reward studies that span the spectrum of behavioral health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, and co-morbid conditions and examining the physical, psychological, social and economic effects of lung cancer. | Pre-Application: May 28, 2024; Application: August 7, 2024. | |
| International | Target ALS Biomarker Consortia: Disease Stratification and Progression | Up to USD $500,000 per year for 2 years. | This call is focused on bringing investigators together to work collaboratively on ALS biology with the aim of identifying novel ALS disease progression biomarkers. Only collaborative projects will be considered. Target ALS is particularly interested in supporting projects that propose the study of: Cryptic exons and cryptic exon-related biomarkers, Biomarkers with utility in ongoing or upcoming therapeutic trials and Biomarkers for patient population stratification for specific therapeutics | Letter of Intent: May 29, 2024; Proposal (by invitation): August 21, 2024. | |
| Internatinal | The Obesity Society Awards: Various Opportunities | $1,000 to $5,000 USD; amount varies by award. | These awards recognize specific research achievements as well as other major contributions to the basic science, treatment and prevention of obesity. The Society’s prestigious awards also highlight the careers of obesity researchers. | May 31, 2024. | |
| International | American Society for Laser Medicine and Surgery (ASLMS) Research Grants: A. Ward Ford Memorial Research Grant | Up to USD $65,000 for 1 year. | For direct clinical or basic science research investigating current use or potential new applications of laser or other light based therapy. | June 1, 2024. | |
| International | The ZOLL Foundation: Early-stage research funding | Typically in the $10,000 - $50,000 range | The ZOLL Foundation provides grants, often seed funding, to young investigators conducting research that improves care for patients suffering from serious cardiopulmonary and respiratory conditions. | June 3, 2024. | |
| International | International Centre for Responsible Gaming (ICRG): Research on the Language and Messaging of Prevention and Responsible Gambling Programs | Up to USD $402,500 for 3 years. | This is for studies that investigate the impact of safer gambling messaging including its impact on gambling behavior and use of responsible gambling tools. | June 3, 2024. | |
| International | American Psychological Foundation (APF): F.J. McGuigan Early Career Invesigator Research Grant on Understandin the Human Mind | USD $15,000. | To recognize and support the efforts of an early career psychological scientist who is pursuing research that aims to address any aspect of mental function (e.g., cognition, affect, motivation) and seeks to understand the mind from both a behavioral and neural perspective. | June 5, 2024. | |
| International | Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery | Up to USD $75,000 per project. | These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes. | Letter of Intent: June 7, 2024. Full Proposal (by invitation): August 30, 2024. | |
| International | Michelson Prizes: Next Generation Grants | USD $150,000. | The Michelson Prizes are looking for applications related to Human Immunology and Vaccine Research. This supports research that aims to tackle the current roadblocks in human vaccine development and expand our understanding of immune processes fundamental to successful vaccine and immunotherapy development. Research with potential applications across multiple disease areas and states is of particular interest. | June 9, 2024. | |
| International | International Centre for Responsible Gaming (ICRG): Research on Sex and Gender and Gambling | Up to USD $172,500 for 2 years. | This will fund a large grant to study the relationship between sex, gender identities, gender roles and/or sexual orientation as factors in gambling and problematic gambling. | June 10, 2024. | |
| International | American Psychological Foundation (APF): Wayne F. Placek Grants | Up to USD $15,000. | Encourages research to increase the general public’s understanding of homosexuality and sexual orientation, and to alleviate the stress that lesbian women, gay men, bisexual women, bisexual men, and transgender individuals experience in this and future civilizations. | June 12, 2024. | |
| International | American Psychological Foundation (APF): The Springfield Research Fund Grants | Up to USD $21,000. | Supports research of contemporary LGBTQIA+ issues in an effort to dispel stereotypes and other negative information that leads to prejudice and discrimination. Applicants must be early career psychologists no more than 10 years postdoctoral. | June 12, 2024. | |
| International | American Association for Hand Surgery (AAHS) Annual Research Grant | Range USD $5,000-$15,000 for 1 year. | These are awarded to clinicians and therapists in private or academic practice for small clinical studies focused in hand care, or for pilot studies leading to a more major hand care study. There may be up to 3 co-investigators on a project and at least 1 of the investigators MUST be an Active or Affiliate AAHS member. | June 15, 2024. | |
| International | Mendez National Institute of Transplantation Foundation (MNITF): Research Grant Program | Up to USD $150,000 for 2 years. | This grant program continues the vision and legacy of our founders by awarding grants semiannually to researchers to improve clinical outcomes and positively impact the field of transplantation. MNITF prioritize projects that could make a significant, immediate impact on advancing transplantation and for which funding is not available from other sources | Two cycles available Letter of intent: June 15, 2024; November 1, 2024. Full application: July 31, 2024; December 15, 2024. | |
| International | International Centre for Responsible Gaming (ICRG): Research on Gambling Industry Employees | Up to USD $172,500 for 2 years. | This invites investigators to propose research projects that will study the possible gambling related harms and other potential risks to health, of working in the gambling industry. | June 24, 2024. | |
| International | Retina Society: Research Grant | USD $50,000. | Supporting the advancement of knowledge and education throughout the global retina community, The Retina Society established this research and education grant program to fund annual innovative research grants by Retina Society members in good standing. The applications should fall in one of two categories: basic science/translational research or clinical research. | June 30, 2024. | |
| International | Radala Foundation- Advanced Research Grants in ALS | 200,000 CHF for 2 years. | The Radala Foundation is looking for established, leading principal investigators eligible for research funding to pursue a potentially ground-breaking, high-risk project for 2 years in basic research in ALS. | June 30, 2024. | |
| International | Sigma Theta Tau International Honor Society of Nursing: Sigma/American Nurses Credentialing Center Evidence-Based Practice Implementaton Grant | USD $20,000. | This opportunity encourages nurses in clinical settings to apply evidence to practice and evaluate the effects on patient outcomes. | July 1, 2024. | |
| International | Sigma Theta Tau International Honor Society of Nursing: Sigma/Doris Bloch Research Award | USD $5,000. | This award encourages nurses to contribute to the advancement of nursing through research. Allocation of funds is based on the quality of the proposed research, the future promise of the applicant and the applicant's research budget. | July 1, 2024. | |
| International | Paralyzed Veterans of America: Research Grants and Fellowships | Up to USD $200,000 for up to 3 years. | This supports innovative research and fellowships that improve the lives of those with spinal cord injury and disease (SCI/D). Projects should be designed to find better treatments and cures for paralysis and support efforts to improve the quality of life of individuals with SCI/D until improved clinical treatments, technologies or cures are discovered. The grant funds in the categories: basic science, clinical, design and Development and Fellowships. | July 1, 2024. | |
| International | American Psychological Foundation (APF): Marian R. Stuart Grant | Up to USD $20,000. | To further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicants must be early career psychologists no more than 10 years postdoctoral. | July 10, 2024. | |
| International | US Department of Defense (DOD) Office of the Congressionlly Directed Medical Research Programs: The Lung Cancer Research Program (LCRP) - Patient-Centered Outcomes and Surviorship Award | Up to USD $650,000 for up to 3 years; Level 2 (clinical trial option): Up to $1.2M for up to 4 years. | Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. | Pre-Application: July 17, 2024; Application: August 7, 2024. | |
| International | E.W. "Al" Thrasher Awards | Up to USD $550,000 for up to 3 years. | This is for projects that are changing pediatric clinical care. Each award is a novel approach to problems plaguing pediatrics. Thrasher's focussi on child outomces - to fund science that will make meaningful progress in the way diseases are diagnosed and treated. | Spring 2025 cycle: Concept Submission: July 18, 2024; Full Proposal: October 20, 2024. | |
| International | Cystic Fibrosis Foundation: Path to a Cure - Collaborative Research Grant | $1,000,000/year for up to three years. | This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches. | July 29, 2024. | |
| International | American Orthopaedic Society for Sports Medicine (AOSSM): Kirkley Clinical Outcomes Grant | USD $20,000. | This provides start-up seed or supplemental funding for an outcome research project or pilot study. | July 31, 2024. | |
| International | Society for Emergency Medicine (SAEM) Foundation (SAEMF): Various Opportunities | $6,000-$300,000 for 1 year or up to 2 years (check opportunities for amounts) | This foundation provides grants to national and international universities and mediclal schools to help fund innovative research and education initatives in the field of emergency medicine. | August 1, 2024. | |
| International | American Orthopaedic Society for Sports Medicine (AOSSM): AOSSM-JRF Ortho Allograft Research Grant | Up to USD $50,000. | Applications must describe a basic science or a clinical research project surrounding viable Osteochondral Allograft (OCA) transplantation or meniscus allograft transplantation of the knee. Any investigative team seeking this grant must include at least one member of AOSSM in good standing. | August 15, 2024. | |
| International | American Psychological Foundation (APF): Division 39 Marsha D. mcCary Fund Grant for Psychoanalysis | Up to USD $10,000. | This encourages and supports programs in education, research, and service that will advance the profession and keep the psychological community and the public informed of developments in psychoanalytic scholarship, research, and practice. | August 31, 2024. | |
| International | American Psychological Foundation (APF): Bruce and Jane Walsh Grant in memory of John Holland | USD $19,000. | Supports scientific, scholarly, or applied research and/or educational activities investigating how personality, culture, and environment influence work behavior and health (mental and physical). Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral). | September 18, 2024. | |
| International | American Psychological Foundation (APF): Scott and Paul Pearsall Grant | USD $10,000. | Supports graduate and early career work that seeks to increase the public’s understanding of the psychological pain and stigma experienced by adults living with visible physical disabilities, such as cerebral palsy. | October 2, 2024. | |
| International | American Psychological Foundation (APF): Dr. Diana Slaughter Kotzin and Mr. Joseph G. Kotzin Fund Grant | USD $9,500. | Supports research, practice, or education of an early career psychologist on the topic of child and youth suicide among African Americans. | October 2, 2024. | |
| International | Combating Antibiotic Resistant Bacteria (CARB-X) | -- | CARB-X is accepting expressions of interest (EOI) for any of their four funding themes: (1) Therapeutics for infections caused by Gram-negative pathogens (2) Prevention of invasive diseases (3) Diagnostics for neonatal sepsis and (4) Proof-of-concept for alternative sample types for diagnosing lower-respiratory-tract infections. In the EOI, you will be asked to answer a series of questions about your proposed project and will be given the opportunity to share pertinent, non-confidential details. | October 4, 2024. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions | Up to USD $34,000. | This will fund the research of psychologists for evidence-based research and intervention in providing mental health training dissemination to first responders in rural areas. | October 23, 2024. | |
| International | American Psychological Foundation (APF): John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions | $34,000 | The APF John and Polly Sparks First-Responder Grant will fund research to examine evidence-based interventions to protect the mental health of first responders in rural areas, conducted by psychologists. | October 23, 2024. | |
| International | Gateway for Cancer Research: Various Opportunities | Typically in the $200,000 to $1.5 million range for 2-5 years | Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. Gateway funds treatment-based studies at the bedside, including all types of cancers. Research areas include Biomarkers (prognostic or predictive with supportive treatment), Gene Therapy, Basket Trials, Immunotherapy, and Targeted Therapies. | Rolling deadlines 3x per year. Anticipated deadlines for 2024: July or August, and November or December. | |
| International | US Department of Defense (DOD) Pre-announcement: Amyotrophic Lateral Sclerosis Research Progam for FY24 - Pilot Clinical Trial | Up to $2,000,000 for up to 4 years. | 1) Supports exploratory clinical trials of novel therapeutics or devices to demonstrate feasibility and inform the design of more advanced trials in ALS. 2) Supports clinical trials that may optimize aspects of multi-disciplinary ALS care or therapies for symptom management. 3) Must support a clinical trial and may not be used for preclinical research studies. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Pre-announcement: Amyotrophic Lateral Sclerosis Research Progam for FY24 - Clinical Outcomes and Biomakers Award | Up to $750,000 for up to 3 years. | 1) Supports development, improvement, and validation of clinical outcomes and/or biomarkers to enrich clinical trials in ALS. 2) Biomarker analysis can be relevant to a specific therapeutic or a specific ALS subtype and does not have to broadly apply to all patients. 3) A description of the biomarker category and intended context of is an important component. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Pre-announcement: Amyotrophic Lateral Sclerosis Research Progam for FY24 - Therapeutic Development Award | Up to $1,500,000 for up to 3 years. | 1) Supports secondary preclinical validation and/or Investigational New Drug (IND)-enabling studies of therapeutics for ALS. 2) Preliminary data are required including therapeutic efficacy in at least one ALS model system. 3) Mechanism-specific predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Pre-announcement: Amyotrophic Lateral Sclerosis Research Progam for FY24 - Pilot Clinical Trial - Therapeutic Idea Award | Up to $600,000 for up to 2 years. | 1) Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS. 2) Projects focusing primarily on ALS pathophysiology, without consideration of therapeutic development, are outside the scope of this award mechanism. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD)Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Clinical Trial Award | Research Level 1: Up to USD $500,000 for up to 3 years; Research Level 2: Up to USD $2M for up to 4 years; Research Level 3: Up to USD $4M for up to 4 years. | Supports the rapid implementation of clinical trials with the potential to have a significant impact on psychological health conditions and/or TBI through clinical applications, including healthcare products, technologies, and/or practice guidelines. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - FocusedProgram Award | $5M for up to 4 years. | Supports high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary Supports the development of a synergistic, multidisciplinary research program with the potential to have a significant impact on TBI and/or PH. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Health Services Research Award | Up to USD $2.5M for up to 4 years. | Bridges the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Translational Research Award | Research Level 1: Up to USD $500,000 for up to 3 years; Research Level 2: Up to USD $1M for up to 4 years. | Supports the conversion of research findings in psychological health and/or TBI into clinical applications, including health care products, technologies, and/or clinical practice guidelines. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRPP) Pre-Anouncement: FY24 Trauamtic Brain Injury and Psycholgical Health Research Program (TBIPHRP) - Emerging Research Award | Research Level 1: Up to USD $700,000 for up to 3 years; Research Level 2: Up to USD $1.5M for up to 4 years. | Advances research in emerging topics in in traumatic brain injury and/or psychological health, with a unique set of topic areas aligned with TBIPHRP goals (see website for details). | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Pre-Announcement: FY24 Military Burn Research Program (MBRP): Various Opportunities | Check opportunities for amounts & durations | Applications submitted to the FY24 MBRP must address one or more of the following Focus Areas: Atypical Burns; Burn Knowledge Products; Burn injury-related complications; Development and/or validation of methods to prevent, assess, and/or treat burn injury-related complications, including: Over/under fluid resuscitation to include limited or low-volume resuscitation, Acute respiratory distress syndrome (ARDS), Sepsis, Inhalation injuries, Peripheral neuropathy, Chronification of pain (prevention only). | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Pre-Announcement: Multiple Sclerosis Research Program (MSRP): Multiple Opportunities | Check opportunities for amounts & durations | The MSRP is providing the information in the pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. Applications submitted to the FY24 MSRP must address one or more of the following focus areas relevant to the award mechanisms as described on the FY24 MSRP website. | Deadlines will be available when the announcements are released. | |
| International | US Department of Defense (DOD)Pre-Announcement: Congressionally Directed Research Programs (CDMRP): FY24 Peer Reviewed Cancer Research Program (PRCRP) - Multiple Opportunities | USD $400,000 - $20,000,000 (check opportunities for amounts) | The FY24 PRCRP will provide funds for research into cancers not addressed in the other CDMRP cancer programs. To be considered for funding, applications for the FY24 PRCRP must address at least one of the FY24 PRCRP Topic Areas. The FY24 PRCRP requires all applications to answer at least one of the Military Health Focus Areas listed on the opportunity website. | Deadlines will be available when the announcments are released | |
| International | Jeffrey Modell Foundation: Specifc Defect Research Program | up to USD $50,000 for 2 years | Supports research that studies the mechanisms and presentation of specific defects of the immune system to gain a better understanding of the defects and their impact on overall health outcomes. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | Jeffrey Modell Foundation: C.H.I.L.D.R.E.N!® | up to USD $25,000 for 2 years | Supports research focused on children living with PI throughout the world, while addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment. | Applications are accepted and reviewed on a rolling basis, so you may apply at any time. | |
| International | Biogen: Various Opportunities | -- | Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in Medical Education, Patient Educaiton and General Grant. | April 15, August 15, November 1. | |
| International | American Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research Grant | USD $20,000 for 1 year. | The funds are dedicated to the support of psychoanalytic research and scholarship, while nuturing the development of psychoanalytic investigators. | May 1 and December 31 of each year. | |
| International | AlloSource: Investigator Initiated Research (IIR) Grant Program | Grant requests may include project funding and/or implantable tissue. | AlloSource is working closely with physicians and scientists across multiple orthopedic therapies to continuously improve and bring new allografts to the market, while simultaneously maximizing the gift of donation. | Rolling Deadline | |
| International | Solving Kids' Cancer Therapeutic Development Initiative (TDI) | $50,000 to $500,000 USD for up to 2 years. | Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. | Preliminary Proposal Deadline: Rolling | |
| International | Össur Orthopaedic Research Grant Program | -- | This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics. | Rolling Deadline | |
| International | Aesculap Implant Systems Investigator-Initiated Study Program (IIS) | Dependent on the type of research and availability of support. | This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics. | Continuous | |
| International | Bausch + Lomb Grants | -- | Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. | Rolling Deadlines. Allow 6-12 weeks for proposal review and decision. | |
| International | Horizon Europe Pillar II: Global Challenges and European Industrial Competitiveness | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | Canadian researchers can now apply for and receive funding directly from this program. Pillar II funding is organised into 6 clusters (i.e., themes), including Cluster 1: Health. A consortium of at least three partners is needed to apply: at least one must be from an EU country and two must be from different EU or associated countries (e.g., Canada). | Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines. | |
| NIH | NIH Parent Announcements | -- | This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases. | https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm | |
| NIH | NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). | February 9, 2024; May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV | -- | This is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) | -- | This Grant program supports exploratory and innovative research projects, which fall within the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH). These studies may involve considerable risk, but may lead to breakthroughs in important areas of neuroscience, or to the development of novel techniques, reagents, methodologies, or models of high value to the neuroscience program. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research | -- | This is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health. | This Notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) | -- | This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis | -- | This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships | This notice applies to receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide | -- | This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response. | This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities | -- | This notice encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities. | This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure | -- | This noticeis to highligh interest in research applications to optimize health communication strategis that advance HIV prevention, treatment and cure. | This notice applies to due dates on or after April 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | -- | The National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries. | This notice applies to subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research | -- | This invites applications for small research grants that align with the goals of the National Academy of Medicine's Healthy Longevity Grand Challenge, as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). | This Notice applies to due dates on or after July 16, 2023 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) | -- | This is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | February 5, 2024; June 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings | -- | The purpose is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioral (MEB) health in school settings. | This Notice applies to due dates until June 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities | -- | The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations. | This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): BRAIN Initiative- Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) | -- | This notice solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative (The Brain Research through Advancing Innovative Neurotechnologies) or to enhance our understanding of the brain. | June 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health | -- | This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. | This notice applies to subsequent receipt dates through June 8, 2024. | |
| NIH | NIH: Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed) | Up to $500,000 per year for up to 5 years. | This notice invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. | June 10, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed) | -- | This opportunity invites applications proposing to establish multi-scale computational models recapitulating dynamic changes associated with aging and Alzheimer’s disease (AD) and AD-related dementias (ADRD). | June 13, 2024. | |
| NIH | NIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed) | -- | This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. | June 14, 2024. | |
| NIH | NIH Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial Not Allowed) | -- | This notice is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Research Centers (RCs). The CREID Network serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. Multi- and interdisciplinary teams of domestic and international investigators will conduct innovative, collaborative, hypothesis-driven One Health based research, will undertake outbreak-related research. | June 21, 2024. | |
| NIH | NIH Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (U01 Clinical Trial Not Allowed) | -- | This notice is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (CC). The CREID Network serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. | June 21, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) | -- | The National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS. | This notice applies to due dates on or after March 14, 2023, and subsequent receipt dates through June 24, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) | -- | The purpose on the NOSI is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) / acute lung injury (ALI). | This notice applies to receipt dates through July 5, 2024. | |
| NIH | NIH: Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trials Optional) | Up to $350,000 in direct costs/year for up to 5 years | This notice of funding opportunity (NOFO) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction which may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. | Letter of Intent: June 17, 2024 Full Application: July 17, 2024. | |
| NIH | NIH: Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial Optional) | Up to $500,000 per year for up to 5 years | This notice is to foster development and testing of technologies adaptable to aging-related changes in older adults (aged 65 years or older) with T1D to improve diabetes management and quality of life. Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. Projects will be funded to a) develop and test new technologies and b) to adapt and test existing technologies. | July 17, 2024. | |
| NIH | NIH Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed) | -- | This supports support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required. | July 30, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Devide Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | -- | The purpose of this NOFO is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented oppotuties to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process | August 13, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Mechanistic Studies on Social Behavior in Substance Use Disorder (SUD): R01 Clinical Trials Not Allowed | Up to $425,000 for up to 5 years | This is intended to support basic or translational research in non-human animal models, including secondary analysis of data from research in animal models. that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of SUDs and comorbidities. | Letter of Intent: July 14, 2024; Full Application: August 14, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Mechanistic Studies on Social Behavior in Substance Use Disorder (SUD): R01 Clinical Trials Optional | -- | This will support projects that investigate social behavior and its relationships with the onset, trajectory, and impact of SUDs and comorbidities. It is intended to support basic or early translational studies that may, but need not, be considered NIH clinical trials; this may include mechanistic clinical trials, observational studies, or secondary analysis of human data. | Letter of Intent: July 14, 2024; Full Application: August 14, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Mechanistic Studies on Social Behavior in Substance Use Disorder (SUD): R01 Basic Experimental Studies with Humans (BESH) Required | -- | This is to solicit applications proposing studies that meet the NIH definition of Basic Experimental Studies involving Humans (BESH) and consist of mechanistic, transdisciplinary research on social behavior and its relationships with the onset, trajectory, and impact of SUDs and comorbidities. | Letter of Intent: July 14, 2024; Full Application: August 14, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning | -- | This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data. | This notice applies to subsequent receipt dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 | -- | National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | -- | The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping toaccor or marijuana on the risk onf acquiring COVID-19 and the clinical course of the infection. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Basic Research in Cancer Health Disparities: R01 Clinical Trial Not Allowed | -- | These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Basic Research in Cancer Health Disparities: R21 Clinical Trail Not Allowed | -- | This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Basic Research in Cancer Health Disparities: R03 Clinical Trail Not Allowed | -- | These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. | This notice applies to due dates through September 8, 2024 | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions | -- | This notice is intended to stimulate the use of behaviour economies strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research | -- | The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | -- | This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. It is expected that the the tools developed will be made widely available to the neuroscience research community for their use and modification. | September 12, 2024. | |
| NIH | NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | -- | This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfil an unmet need and are capable of enhancing our understanding of life, science processes or the pracice of medicne. | May 24, 2024; September 26, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Influences of Gender as a Social and Structural Variable | -- | This notice is to highlight interest in receiving research and training grant applications focused on health impacts of gender-related social and structural variables. For this notice, relevant domains of gender roles and norms, gender relations, gender equity/inequity, gender equity/inequality, gender-related power dynaics, and structural sexism. | September 30, 2024. | |
| NIH | NIH: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This opportunity is for applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This opportunity invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This opportunity solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care.The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. | April 1, 2024; October 1, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This opportunity solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. | April 1, 2024; October 1, 2024. | |
| NIH | NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | _ | The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. | February 2, 2024; June 4, 2024; October 2, 2024. | |
| NIH | NIH BRAIN Initative: Targeted BRAIN Circuits Planning Projects - TargetedBCP: R34 Clinical Trials Not Allowed | -- | For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying hat, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01 | June 28, 2024; October 2, 2024. | |
| NIH | NIH BRAIN Initative: Targeted BRAIN Circuits Planning Projects - TargetedBCP: R01 Clinical Trial Not Allowed | -- | For research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. | June 28, 2024; October 2, 2024. | |
| NIH | NIH: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | -- | This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research. | June 5, 2024; October 5, 2024. | |
| NIH | NIH: Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes: Effectiveness Trials (R01 Clinical Trial Required): | -- | NIMH seeks applications for research projects to evaluate the effectivness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. | This notice for new applications applies to due dates on or after June 5, 2024 and subsequent receipt dates for new or resubmission applications through October 5, 2024. | |
| NIH | NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) | -- | The National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research. | June 7, 2024; October 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | -- | The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings or during care transitions. Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. | This notice applies to subsequent receipt dates through October 9, 2024. | |
| NIH | NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | -- | The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. | February 13, 2024; June 11, 2024; October 11, 2024. | |
| NIH | NIH: Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes: Pilot Effectiveness Trials (R34 Clinical Trial Required) | Up to $450,000 for up to 3 years. | This is support pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. | This notice for new applications applies to due dates on or after June 16, 2024 and subsequent receipt dates for new or resubmission applications through October 16, 2024. | |
| NIH | NIH: Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) | Up to $500,000 per year for up to 2 years for the UG3 phase and up to $1,500,000 per year of the UH3 phase for up to 5 years in total for the UG3/UH3 phase. | This is to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. | October 18, 2024. | |
| NIH | NIH Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) | -- | This is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. | October 18, 2024. | |
| NIH | NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) | -- | This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials | This notice applies to subsequent recipt dates through November 6, 2024. | |
| NIH | NIH: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) | -- | This is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA. | This notice for new applications applies to due dates on or after March 11, 2024 and subsequent receipt dates for new or resubmission applications through November 12, 2024. | |
| NIH | NIH: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trail Optional) | -- | This is to invite applications proposing new tests, animal models, techniques, etc. to advance on Alzheimer's disease (AD) and its related ementias (ADRD) that need additionl preliminary data with broader dissemination to establish them for more general use in this research field. | This notice for new applications applies to due dates on or after March 11, 2024 and subsequent receipt dates for new or resubmission applications through November 12, 2024. | |
| NIH | NIH: Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) | Up to $275,000 for 2 years. No more than $200,000 may be requested in any single year. | This notice is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. Exploratory projects are appropriate for this notice. | November 13, 2024. | |
| NIH | NIH: Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R01 Clinical Trial Not Allowed) | -- | This notice is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this notice. | November 13, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Interventions to Reduce Chronic Inflammation and Inflammation-Related Morbidity in People Living with HIV/AIDS | -- | This notice encourages applications for clinical and basic and mechanistic research to develop, refine, and/or test interventions that reduce or prevent chronic HIV-associated inflammation, and evaluate whether this ultimately reduces the sequelae of that inflammation. This notice does not support applications proposing an intervention to address acute inflammation, such as that occurring after an injury and/or non-HIV infection. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 14, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) | -- | The purpose is to invite applications proposing innovative analysis of exisiting social science, behavioural, administrative, and neuroimaging data to study the etiology and epidermiology of substance using behaviours (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. | March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Opional) | -- | The purpose is to invite applications proposing innovative analysis of exisiting social science, behavioural, administrative, and neuroimaging data to study the etiology and epidermiology of substance using behaviours (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. | March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | -- | The opportunity invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | -- | This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | -- | This invites Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | -- | This invites exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | June 11, 2024; November 15, 2024. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) | -- | The purpose is to solicit application for research targeted at eludicating the effect of HIV and/or anit-retroviral therapy on the growth, development and functioning of the placenta in pregnant individuals with substance use/misuse, the impact of placental abnormalities on maternal outcomes, and the underlying mechanisms. | November 16, 2024. | |
| NIH | NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | -- | This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). | December 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research | -- | This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. | This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024. | |
| NIH | NIH R21: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) | -- | The purpose of this is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) | -- | This opportunity seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). | This notice applies to due dates on or after May 7, 2024, and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH: Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) | -- | This opportunity encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope. | This notice applies to subsequent recipt dates through January 8, 2025. | |
| NIH | NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest | -- | This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals. | This notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) | -- | To stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics. | Standard dates apply until January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research | -- | National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. | This Notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. | This notice applies to due dates on or after February 8, 2024 and subsequent receipt dates through February 10, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through February 16, 2025. | |
| NIH | NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | -- | The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through February 19, 2025. | |
| NIH | NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) | -- | This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. | February 20, 2024; August 19, 2024; February 19, 2025. | |
| NIH | NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | -- | This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation. | March 15, 2024; March 14, 2025. | |
| NIH | NIH Tobacco Regulatory Science (R01 Clinical Trial Optional) | -- | This is to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). | This notice applies to due dates on or after May 6, 2024 and subsequent receipt dates through May 2, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis | -- | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. Applicants are required to measure and report results using a standard THC unit in all applicable human subjects research. | This notice applies to subsequent receipt dates through May 5, 2025. | |
| NIH | NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | -- | This notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. While there has been signficant progress identiying and intervening on risk and protective factors for substnce use, population-level impact of substance use prevention interventions has not yet been achieved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening | -- | This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | -- | This encourages applications proposting to test multilevel strategies and interventions to improve the update of evidence-based screening services across the lifespan and in populations including, but not limited to those experiencing health disparties and those that are underserved. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | -- | The goal is to stimulate the use of exisiting human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tool, ethods that hev the potential for significant impact in areas relevant to the NEI mission. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH National Eye Institute (NEI) Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | -- | This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. This supports applicants in their planning efforts to conduct collaborative clinical research. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | This notice applies to subsequent receipt dates though May 8, 2025. | |
| NIH | NIH Mutiple-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective it to present the scientific rationale for the clinical trial and a comprehensive scientific and operation plan that describes it. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) | -- | This supports applicatins to develop and implement a Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effeciveness, pragmatic and/or implementation research clinical trials. The objective is to present a comprehensive plan to provide overall project coordination, administration, data management and biostatistical support for the clinical trial proposed. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | -- | This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025. | |
| NIH | NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This does not support research on basica cancer biology, late-stage clinical trials, risk assessment studies, epidemiological studies or studies of behavioral interventions. | This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 12, 2025. | |
| NIH | NIH Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | -- | Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 16, 2025. | |
| NIH | NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | -- | This supports efforts to optimize and evaluate pharmacodynamic (PD) measures the neurophysiological processes that are disrupted within or acoss mental disorders in both healthy humans and in another species relevant to the therapuetic development pipeline. This initative will support inital proof of concent studies aimed at identifying meaures for potential development as preclinical assas for evaluating potential new drug and device therapies and their targets. | This notice applies to due dates on or after February 21, 2024 and subsequent receipt dates through June 20, 2025. | |
| NIH | NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | -- | This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used there in. The goal is to improve the translational application of animal models and/or outcome measures for the development of non-addicitve analgesics. | This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | -- | This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. | This notice applies to due dates on or after February 27, 2024 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy | -- | This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest. | This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations | -- | This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. | This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025. | |
| NIH | NIH Notice of Funding Opportunity (NOFO): Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | -- | This is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. | August 2, 2024; August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | -- | This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. | This notice applies to subsequent receipt dates through August 1, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) | -- | This NOSI supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with Substance Use Disorders (SUD). | This notice applies to due dates on or after July 15, 2023 and subsequent receipt dates through August 15, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | -- | This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations or 3-D multi-cellular in vitro systems of human lung cells and will employ state-of-art multi-omics measures. | This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | -- | This notice is to solicit projects on preventive interventions that address cardiometabolic risk factors across the lifespan in populations that experience health disparities. | This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | -- | This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. | This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | -- | This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams. | This notice applies to subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information | -- | This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making. | This notice applies to subsequent receipt dates through September 24, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes | -- | This notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into healthcare settings. It is to encourage intervention research focused on addressing exposure to violence to improve individual-level health processes and outcomes. | This notice applies to subsequent receipt dates through October 5, 2025. | |
| NIH | NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | -- | This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2025. | |
| NIH | NIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | -- | This supports small research projects on cancer that can be carried out in a short period of time with limited resources. | This notice applies to due dates on or after February 22, 2024 and subsequent receipt dates through October 17, 2025. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH HEAL Initative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed) | -- | This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data | -- | This notice is to highlight its interest in recieving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets. This invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses | -- | This will fund research on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Innovations to Optimize HIV Prevention and care Continuum Outcomes (R34 Clinical Trials Optional) | -- | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention. | This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026. | |
| NIH | NIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | -- | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through January 13, 2026. | |
| NIH | NIH BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) | -- | Seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | -- | This seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. | This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | -- | National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior | -- | The notice encourages collaborations between computtionally and experimentally focused investigators. It seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations after cognitive, affective, or social processing in humans or animals | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | -- | This invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. This notice will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signatur. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH: SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This opportunity encourages applications for multi-center clinical trials focused on neurological emergencies (excluding stroke). The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. | This notice applies to due dates on or after June 10, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This encourages applications for multi-center clinical trials focused on neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. | This notice applies to due dates on or after February 6, 2024 and subsequent receipt dates through February 6, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): School Mental Health: Innovative Approaches to Expand Access to Evidence-Based Interventions and Services | -- | This notice is to outline priorities for school-based intervention and services research and encourages applications that incorporate: (1) end-user/community-engaged approaches with systematic attention to challenges related to gaining access to schools, competing demands/workload issues, workforce shortages, and privacy concerns; (2) research-practice partnerships that leverage existing practice infrastructure (3) plans to quantify the resources necessary to implement the intervention, tool, or strategy; and (4) strategies that promote health equity. | This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through March 17, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | -- | This notice will support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through May 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | -- | This notice is to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related, geographic, cultural considerations, and health disparities influence the types of care that are provided. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025. | |
| NIH | NIH NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) | -- | This encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the National Institute of Allergy and Infectious Diseases (NIAID). | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through May 13, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to Eludicate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Secondary Analysis and Integration of Exisiting Data to eludicate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | -- | This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R01 clinical Trial Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Social disconnection and Suicide Risk in Late Life (R21 clinical Trials Not Allowed) | -- | This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026. | |
| NIH | NIH BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed) | -- | This seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation. | This notice applies to due dates on or after June 18, 2024 and subsequent receipt dates through June 15, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Clinical Trial Optional) | -- | Studies proposed should identify and validate new neuromodulation targets and provide a comprehensive understanding of the behavioral and neurobiological effects of stimulation to these targets and their constituent brain networks. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatement (R01 Basic Experiemental Studies wth Humans Required) | -- | For studies that meet both the definition of basic research and the NIH definition of a clinical trial. Types of studies that should submit include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Mechanistic Research on Neuromodulation for Substance Use Disoders Treatement (R61/R33 Clinical Trial Optional) | -- | Supports applications that are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. | This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional) | -- | This seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment | -- | This notice solicits applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment | -- | This notice solicits theoretically- and empirically-driven research applications which will: 1) advance measurements and understanding of HIV-related ISD or intersectional social-structural factors to examine the mechanisms and pathways by which they are barriers to HIV prevention and HIV treatment; 2) develop and test interventions to address their impact to improve HIV prevention and HIV treatment outcomes; or 3) conduct implementation science research of evidence-based interventions. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH R21: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | -- | This notice is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). | This notice applies to due dates on or after October 16, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on HIV-associated Malignancies | -- | This notice calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of malignancies, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. | This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026. | |
| NIH | NIH Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | -- | This notice is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. It is to seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH Notice of Funding (NOFO) - Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | -- | This seeks to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: National Cancer Institute's (NCI) Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | -- | The NCI is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the Division of Cancer Treatment and Diagnosis (DCTD), and Office of HIV and AIDS Malignancies (OHAM). | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | -- | This supports investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities | -- | This notice is intended to support the use of the telehealth interventions and tools aimed at the prevention, management and treatment of heart, lung, blood, and sleep conditions, and of cancer in rural communities. The purpose of this notice is to provider-to-provider telehealth (PPT) is defined broadly to include any health technology meant to connect healthcare providers to one another for the care of patients. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through October 9, 2026. | |
| NIH | NIH Prevention and Intervention approaches for Fetal Alcohol Spectrum Disorders (FASD) (R61/R33 Clinical Trial Optional) | -- | This is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disoders (FASD) (R34 Clinical Trial Optional) | -- | This R34 planning grant applications focuses on prevention and intervention strategies for FASD throughout the lifespan. The intent is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI): Small Research Grant (R03 Clinical Trial Optional) | -- | This is for research that examines the ELSI of human genetic or genomic research. Applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. | This notice applies to due dates on or after February 19, 2024 and subsequent receipt dates through October 16, 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | -- | This is for studies of the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI):Research (R01 Clinical Trial Optional) | -- | This is for applications that propose to study the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods. | This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026. | |
| NIH | NIH: Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research | -- | This notice encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research. This will support applications that focus on development of allogeneic or xenogeneic OCM to study immunologic features of transplant-related diseases or conditions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through November 16, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | -- | This encourages R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026. | |
| NIH | NIH: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | -- | The purpose of this opportunity is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. | This notice applies to due dates on or after March 26, 2024, and subsequent receipt dates through November 19, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Existing and Accessible Datasets for Implementation Research Strategies and Testing - LEAD FIRST | -- | This notice promotes the use of existing and accessible datasets to inform community-engaged dissemination and implementation (D&I) research on heart, lung, blood and sleep conditions to advance health equity. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) | -- | This notice is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. | This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives (1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and (2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through January 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Core Mission Areas | -- | This will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. | This notice applies to due dates on or after June 16, 2023 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Data Science Research in HIV: Responding to a Dynamic, Complex, and Evolving HIV Epidemic with Artificial Intelligence/Machine Learning | -- | This seeks to advance data science research in HIV by encouraging the generation of cutting-edge synthetic datasets, artificial intelligence, and machine learning approaches to expand our capacity to address the dynamic, complex, and evolving HIV epidemic. | This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia | -- | This is to encourage research on task-based behavioral measures that engage brain systems relevant to anhedonia. These behavioral measures are expected to be used as a proxy for brain target engagement, therefore neuroimaging or other brain measures with similar spatial resolution should be used to demonstrate that the proposed behavioral tasks engage brain systems relevant to anhedonia. | This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | -- | This notice is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027. | |
| NIH | NIH: NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | -- | This notice encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. | This notice applies to due dates on or after May 13, 2024 and subsequent receipt dates through January 13, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Fundamental Mechanisms and Functions of Co-transmission in the Brain | -- | This notice encourages basic neuroscience research in animals to investigate the fundamental mechanisms and functions of co-transmission (i.e., release of multiple neurotransmitters by one neuron) that support brain activity and behavior. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 4, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through February 5, 2027. | |
| NIH | NIH: New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | -- | The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through February 16, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) | This notice is to encourage applications which are focused on development of diagnostics, therapeutics, and vaccines for herpes simplex virus (HSV). The NIH Strategic Plan for HSV Research focuses on four strategic priorities: HSV virology basic research, better HSV diagnostics, strategies to address HSV treatment and cure, and research to prevent HSV infection. This NOSI focuses on furthering the development of new products for prevention of HSV infection, as well as improving the diagnosis and treatment of patients living with herpes, addressing three of these four strategic priorities. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through April 5, 2027. | ||
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through May 7, 2027. | |
| NIH | NIH: Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) | -- | This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 7, 2027 | |
| NIH | NIH Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances | -- | This notice calls for research to build a body of evidence on how to implement and sustain OEND in HIV prevention and care settings. Research should develop and test models for integrating OEND; examine barriers and facilitators to successful implementation; and develop implementation strategies to address provider, organizational, structural, reimbursement and other factors impacting implementation. | This notice applies to due dates on or after May 7, 2024 and subsequent receipt dates through May 8, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors | -- | This notice solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. | This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through May 10, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment | -- | This notice is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. Understanding the heterogeneity of obesity is necessary for precision and targeted implementation of obesity prevention and treatment interventions. | This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2027. | |
| NIH | NIH Notice of Special Interest (NOSI): Women’s Health Research | -- | This notice is to highlight interest in receiving research applications focused on diseases and health conditions that predominantly affect women (e.g., autoimmune diseases; depressive disorders, Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or are female-specific (e.g., uterine fibroids; endometriosis; menopause). | This NOSI applies to due dates on or after May 6, 2024, and subsequent receipt dates through November 4, 2027. | |
| NIH | NIH: Notice of Special Interest (NOSI): Developing and Testing Multi-level Physical Activity Interventions to Improve Health and Well-Being | -- | This notice is to increase and maintain health-enhancing physical activity in a wide range of population groups, including populations that experience health disparities, children, older adults, and persons at risk for mental/behavioral health conditions, and any subpopulations that can be characterized by the intersection of two or more of these descriptors. | This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through November 14, 2027. |
